Skip to main content

Table 3 Adverse events in stage 2

From: Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial

Adverse event Number of adverse events in study
Infusion dose (mg/kg)
1 3 6
hypoglycemia 5 7 24
infusion reactions 0 10 0
URI 13 16 4
diarrhea 0 11 0
pyrexia 1 6 0
cough 3 4 0
sinusitis 4 2 0
otitis media 4 2 0
skin rash 1 4 0
back pain 3 0 2
impetigo 3 0 2
  1. Adverse events listed were observed 5 or more times during course of 52-week study.